Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Myopia - from genes and environment to cellular responses and treatment

Descrizione del progetto

Sbloccare nuove vie per la prevenzione e la terapia della miopia

La visione è regolata da vie biochimiche che controllano la crescita dell’occhio: una via inibitoria che sopprime la crescita dell’occhio, attivata quando le immagini si concentrano davanti alla retina, e una via stimolatoria, attivata quando le immagini si concentrano dietro di essa. Chi soffre di miopia vede gli oggetti lontani in modo sfocato e i trattamenti attuali offrono solo benefici limitati. Con il sostegno del programma di azioni Marie Skłodowska-Curie, il progetto MyoTreat si propone di esplorare i fattori ambientali e genetici che influenzano la miopia. I ricercatori intraprenderanno ricerche interdisciplinari e le combineranno con la diagnostica guidata dall’intelligenza artificiale per identificare nuovi bersagli farmacologici e sviluppare biomarcatori per la diagnosi precoce. L’obiettivo è far progredire la terapia della miopia attraverso strategie innovative che regolano la crescita dell’occhio.

Obiettivo

"In modern industrial societies, myopia has become an important ocular health problem of young people, due to its increased incidence and associated complications, which pose a significant risk of blindness already in the middle life span. Current treatment options have limited effects with a maximum reduction of axial elongation by about 0.4 mm over several years, equivalent to a reduction in myopia by only about 1 D. Eye growth is controlled by an interplay of different biochemical pathways, one inhibitory (stimulated by image plane in front of the retina) and one stimulatory (image plane behind the retina). A novel future strategy would be to activate the inhibitory pathways rather than inhibit the growth stimulating pathways (standard target in most studies). At present, interventions to activate growth inhibition are poorly studied. The influence of environmental factors (spectral composition of ambient light) and gene-environment interactions (specific gene variants and their interaction with key lifestyle exposures) on eye growth and refractive development will be investigated. New pharmacological targets will be identified and tested, and biomarkers established to detect the onset of myopia at an earlier stage. It will be studied how choroidal hypoxia relates to choroidal thinning and axial eye growth and how it interacts with the metabolic processes in the retina and sclera. New measurement techniques will be developed that implement artificial intelligence algorithms to improve diagnostics in myopia studies, especially in the periphery of the visual field. The proposed intersectorial and interdisciplinary ""MyoTreat"" project (including anatomy, physiology, pharmacology, optics, and genetics) will train PhD students in myopia research and generate and disseminate novel research results. The ultimate scientific goal is to identify new strategies for myopia therapy through hypothesis-driven translational research in various animal models as well as in humans."

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-MSCA-2022-DN-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Contributo netto dell'UE
€ 521 078,40
Indirizzo
GESCHWISTER-SCHOLL-PLATZ
72074 Tuebingen
Germania
Regione
Baden-Württemberg Tübingen Tübingen, Landkreis
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Partecipanti (5)

Partner (6)